Log In
Sunday 24th June 2018

Final appeal for lung cancer drug

1st May 2007

Following the decision by NICE in June 2006 not to recommend the drug Pemetrexed for the treatment of mesothelioma, a form of lung cancer linked to asbestos, the final appeal will now be heard in June to determine whether the decision will stand.

The NICE appeals process is part of a series of checks and balances to ensure the right decisions were made. NICE agreed to submit the decision to appeal in December when Eli Lilley, the drug's manufacturer, contested the decision.

Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2018